Product
M281
Aliases
Nipocalimab, JNJ-80202135
4 clinical trials
3 indications
Indication
Autoimmune Hemolytic AnemiaIndication
Myasthenia GravisClinical trial
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label ExtensionStatus: Recruiting, Estimated PCD: 2025-03-20
Clinical trial
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia GravisStatus: Terminated, Estimated PCD: 2020-12-09
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia GravisStatus: Completed, Estimated PCD: 2020-06-25
Clinical trial
A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)Status: Active (not recruiting), Estimated PCD: 2024-10-04